论文部分内容阅读
目的探讨洛铂和顺铂分别联合依托泊苷初治小细胞肺癌的临床疗效及安全性。方法选取武汉大学人民医院118例初治小细胞肺癌患者,采用随机数字表法分为洛铂联合依托泊苷治疗(EL组)和顺铂联合依托泊苷治疗(EP组),每组59例。治疗4个疗程后比较疗效、无进展生存时间(PFS)、总生存时间(OS)和不良反应。结果 EL组PR、ORR、DCR组患者部分缓解(PR)、客观缓解率(ORR)和疾病控制率(DCR)均高于EP组,中位PFS和中位OS均长于EP组,不良反应发生率低于EP组,差异有统计学意义(P<0.05)。结论洛铂联合依托泊苷为初治小细胞肺癌提供了新的治疗方法,该方案的临床疗效好,患者生存时间延长,且具有更低的不良反应发生率,优于顺铂联合依托泊苷方案的效果。
Objective To investigate the clinical efficacy and safety of lobaplatin and cisplatin in combination with etoposide-treated small cell lung cancer. Methods A total of 118 patients with newly diagnosed small cell lung cancer were selected from Wuhan University People’s Hospital. Patients were divided into lobaplatin combined with etoposide (EL group) and cisplatin combined with etoposide (EP group) by random number table. Each group included 59 cases . After 4 courses of treatment, the curative effect, progression-free survival time (PFS), total survival time (OS) and adverse reactions were compared. Results The partial response (PR), objective response rate (ORR) and disease control rate (DCR) in PR, ORR and DCR patients in EL group were significantly higher than those in EP group and the median PFS and median OS were longer than those in EP group. Adverse reactions Rate was lower than EP group, the difference was statistically significant (P <0.05). Conclusion Losoplatin combined with etoposide provides a new treatment for newly diagnosed small cell lung cancer. The clinical efficacy of this regimen is good, the survival time of patients is prolonged, and the incidence of adverse reactions is lower than cisplatin combined with etoposide The effect of the program.